Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.

Hsu S, Nagayama T, Koitabashi N, Zhang M, Zhou L, Bedja D, Gabrielson KL, Molkentin JD, Kass DA, Takimoto E.

Cardiovasc Res. 2009 Feb 1;81(2):301-9. doi: 10.1093/cvr/cvn324. Epub 2008 Nov 24.

2.

Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.

Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA.

J Am Coll Cardiol. 2009 Jan 13;53(2):207-15. doi: 10.1016/j.jacc.2008.08.069.

3.

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice.

Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, Mendelsohn ME, Kass DA.

J Clin Invest. 2009 Feb;119(2):408-20. doi: 10.1172/JCI35620. Epub 2009 Jan 5.

4.

Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.

Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA.

J Mol Cell Cardiol. 2009 Apr;46(4):560-7. doi: 10.1016/j.yjmcc.2008.12.008. Epub 2008 Dec 29.

5.

Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition.

Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF, Kass DA.

J Mol Cell Cardiol. 2010 Apr;48(4):713-24. doi: 10.1016/j.yjmcc.2009.11.015. Epub 2009 Dec 1.

6.

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA.

Nat Med. 2005 Feb;11(2):214-22. Epub 2005 Jan 23.

PMID:
15665834
7.

PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.

Lee DI, Vahebi S, Tocchetti CG, Barouch LA, Solaro RJ, Takimoto E, Kass DA.

Basic Res Cardiol. 2010 May;105(3):337-47. doi: 10.1007/s00395-010-0084-5. Epub 2010 Jan 27.

8.

Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure.

Gong W, Duan Q, Cai Z, Chen C, Ni L, Yan M, Wang X, Cianflone K, Wang DW.

Br J Pharmacol. 2013 Dec;170(7):1396-409. doi: 10.1111/bph.12346.

9.

Protein kinase g iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo.

Blanton RM, Takimoto E, Lane AM, Aronovitz M, Piotrowski R, Karas RH, Kass DA, Mendelsohn ME.

J Am Heart Assoc. 2012 Oct;1(5):e003731. doi: 10.1161/JAHA.112.003731. Epub 2012 Oct 25.

10.

ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.

Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC.

Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1236-43. doi: 10.1152/ajpheart.00100.2009. Epub 2009 Mar 13.

11.

Oxidative stress regulates left ventricular PDE5 expression in the failing heart.

Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y.

Circulation. 2010 Apr 6;121(13):1474-83. doi: 10.1161/CIRCULATIONAHA.109.906818. Epub 2010 Mar 22.

12.

Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition.

Nishida M, Watanabe K, Sato Y, Nakaya M, Kitajima N, Ide T, Inoue R, Kurose H.

J Biol Chem. 2010 Apr 23;285(17):13244-53. doi: 10.1074/jbc.M109.074104. Epub 2010 Feb 22.

13.

cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.

Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA.

Circ Res. 2005 Jan 7;96(1):100-9. Epub 2004 Dec 2.

14.

Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.

Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA.

J Pharmacol Exp Ther. 2008 Aug;326(2):380-7. doi: 10.1124/jpet.108.137422. Epub 2008 May 2.

15.

Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta.

Das A, Xi L, Kukreja RC.

J Biol Chem. 2008 Oct 24;283(43):29572-85. doi: 10.1074/jbc.M801547200. Epub 2008 Aug 21.

16.

Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.

Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA.

Circulation. 2007 Apr 24;115(16):2159-67. Epub 2007 Apr 9. Erratum in: Circulation. 2007 May 22;115(20):e536.

17.

Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.

Patrucco E, Domes K, Sbroggió M, Blaich A, Schlossmann J, Desch M, Rybalkin SD, Beavo JA, Lukowski R, Hofmann F.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12925-9. doi: 10.1073/pnas.1414364111. Epub 2014 Aug 19.

18.

Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart.

Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE.

Eur J Heart Fail. 2008 Dec;10(12):1158-65. doi: 10.1016/j.ejheart.2008.09.016. Epub 2008 Nov 12.

19.

Sildenafil Does Not Prevent Heart Hypertrophy and Fibrosis Induced by Cardiomyocyte Angiotensin II Type 1 Receptor Signaling.

Straubinger J, Schöttle V, Bork N, Subramanian H, Dünnes S, Russwurm M, Gawaz M, Friebe A, Nemer M, Nikolaev VO, Lukowski R.

J Pharmacol Exp Ther. 2015 Sep;354(3):406-16. doi: 10.1124/jpet.115.226092. Epub 2015 Jul 8.

20.

Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.

Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11363-8. Epub 2002 Aug 12.

Supplemental Content

Support Center